DCK

Deoxycytidine kinase

4,168 patent compounds predicted against DCK, 1,922 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL307979	1.00	20/20
SCHEMBL308191	1.00	20/20
SCHEMBL310854	1.00	20/20
SCHEMBL312736	1.00	20/20
SCHEMBL312043	0.86	20/20
SCHEMBL307480	0.83	20/20
SCHEMBL311255	0.79	20/20
SCHEMBL311352	0.79	20/20
SCHEMBL311924	0.79	20/20
SCHEMBL311662	0.78	20/20
SCHEMBL307563	0.78	20/20
SCHEMBL308017	0.74	20/20
SCHEMBL311256	0.73	20/20
SCHEMBL306525	0.73	20/20
SCHEMBL311500	0.72	20/20
SCHEMBL310844	0.71	20/20
SCHEMBL310972	0.71	20/20
SCHEMBL307463	0.71	20/20
SCHEMBL310971	0.70	20/20
SCHEMBL311696	0.69	20/20

Germline variants in DCK on Sugi Variant → ClinVar classifications, population frequency, and predictor agreement (AlphaMissense, SaProt, REVEL) Full DCK gene report on Sugi Atlas → Gene function, pathways, protein structure, constraint & interactions

Clinical trials — most relevant to DCK by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Acelarin First Line Randomised Pancreatic Study	PHASE2/PHASE3	SUSPENDED
Gemcitabine With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer	PHASE3	COMPLETED
Clofarabine Plus Cytarabine in Patients With Previously Untreated Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome	PHASE2	COMPLETED
Autologous Cytokine Induced Killer Cells (CIK) for Chronic Myeloid Leukemia (CML) Patients on Standard Drug Therapy	PHASE2	COMPLETED
Safety, Tolerance, Pharmacokinetic and Antiviral Study of Amdoxovir in Combination With Zidovudine in Adults With HIV	PHASE1/PHASE2	COMPLETED
D-CIK Combined With Chemotherapy for Non-Small Cell Lung Cancer(NSCLC)	PHASE1/PHASE2	UNKNOWN
I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers	PHASE1/PHASE2	NOT_YET_RECRUITING
Effect of Intratumoral Injection of Gene Therapy for Locally Advanced Pancreatic Cancer	PHASE2	COMPLETED
Bryostatin 1 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer	PHASE2	COMPLETED
PKC412 and 5-Azacytidine	PHASE1/PHASE2	COMPLETED
Epirubicin, Docetaxel, and Capecitabine in Treating Women With Stage IIIA or Stage IIIB Breast Cancer	PHASE2	COMPLETED
PRO#0118: Decitabine Plus Mini Flu-Bu	PHASE1	COMPLETED
Open-Label, Dose-Escalation With Expansion to Assess the Safety, Tolerability, and PK of TRE-515 in Subjects With Solid Tumors	PHASE1	RECRUITING
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors	PHASE1	COMPLETED
AZD1775 for Advanced Solid Tumors	PHASE1	COMPLETED
Study of Cytolytic Viral Activation Therapy (CVAT) for Recurrent/Metastatic Nasopharyngeal Carcinoma	PHASE1	UNKNOWN
5-Fluoro-2'-Deoxcyctidine and Tetrahydrouridine to Treat Patients With Advanced Cancer	PHASE1	COMPLETED
Volasertib Combined With Induction Chemotherapy in Acute Myeloid Leukemia	PHASE1	WITHDRAWN
Pacritinib and Chemotherapy in Treating Patients With Acute Myeloid Leukemia and FLT3 Mutations	PHASE1	COMPLETED
Gemcitabine and Radiation Therapy in Treating Patients With Locally Advanced Upper Gastrointestinal Cancer	PHASE1	COMPLETED
A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies	PHASE1	COMPLETED
A Study of PD1 Combined With Dc-cik in the Treatment of Solid Tumors	EARLY_PHASE1	UNKNOWN
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212	EARLY_PHASE1	COMPLETED
3'-Deoxy-3'-[18F] Fluorothymidine and Fludeoxyglucose F 18 PET Scans in Evaluating Response to Cetuximab, Cisplatin, and Radiation Therapy in Patients With Advanced Cancer of the Oropharynx, Larynx, or Hypopharynx	EARLY_PHASE1	COMPLETED
Thymidine Kinase 1 in Risk Assessment for Hereditary Breast /Ovarian Cancer	nan	UNKNOWN
RT201(Tumor Antigen-specific Macrophage Tumor Vaccine)	nan	UNKNOWN
Study of DC-CIK Combined With Chemotherapy for Advanced Solid Tumor	nan	UNKNOWN
Biomarkers in Blood and Tissue Samples From Patients With Epstein-Barr Virus-Positive Hodgkin Lymphoma	nan	COMPLETED
Clinical Research for Azacitidine Combined With Low-dose Dasatinib in Maintenance Therapy of Acute Myeloid Leukemia	nan	UNKNOWN
Concurrent Chemoradiation With or Without DC-CIK Immunotherapy in Treating Locally Advanced Esophageal Cancer	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a DCK binder may also engage these)

Protein	Name	Similarity
Q3MHR2	—	1.000	Q3MHR2 →
Q5ZJM7	—	1.000	Q5ZJM7 →
P43346	—	1.000	P43346 →
P48769	—	1.000	P48769 →
Q5ZMF3	—	1.000	Q5ZMF3 →
Q6DD33	—	1.000	Q6DD33 →
A0A1L8HV70	—	0.998	A0A1L8HV70 →
Q6GPW6	—	0.992	Q6GPW6 →
P0DSV5	—	0.991	P0DSV5 →
Q9XZT6	—	0.991	Q9XZT6 →
A0A7H0DNE5	—	0.990	A0A7H0DNE5 →
P00572	—	0.990	P00572 →
Q8QQ21	—	0.990	Q8QQ21 →
Q9QX60	—	0.990	Q9QX60 →
Q80DS7	—	0.990	Q80DS7 →
P68693	—	0.990	P68693 →
P0DSV6	—	0.989	P0DSV6 →
Q16854	—	0.989	Q16854 →
Q76RA8	—	0.989	Q76RA8 →
Q77TG7	—	0.989	Q77TG7 →
P36590	—	0.987	P36590 →
Q8V2K9	—	0.987	Q8V2K9 →
Q6RZD4	—	0.987	Q6RZD4 →
Q9J579	—	0.987	Q9J579 →
Q9UTC5	—	0.987	Q9UTC5 →
Q8QMQ7	—	0.987	Q8QMQ7 →
P42938	—	0.986	P42938 →
Q80HT9	—	0.986	Q80HT9 →
Q9VZD2	—	0.986	Q9VZD2 →
Q09509	—	0.985	Q09509 →